Advances in the Management of Psoriasis

Advances in the Management of Psoriasis is organized by AchieveCE.

Release Date: 07/31/2024
Expiration Date: 07/31/2027

Description:
With the recent FDA approval of several interleukin-23 antagonists added to the list of biologic response modifiers used in the management of plaque psoriasis, healthcare professionals need to be up-to-date with treatment options for this disease, evidence supporting their use, and patient-specific counseling points for psoriasis medications. Healthcare professionals completing this continuing education program will learn about the underlying pathophysiology of plaque psoriasis, pharmacotherapy options to treat mild, moderate, and severe psoriasis, and how to select the best treatment option for patients based on history, comorbidities, and disease severity.

What you will learn:
Pharmacist Learning Objectives:
At the conclusion of this continuing education activity, the participant will be able to:

• Describe the underlying pathophysiology of plaque psoriasis
• Compare treatment options for the management of patients with plaque psoriasis
• Identify optimal pharmacotherapy selection when provided with a patient case

Nurse / Pharmacy Technician Learning Objectives:
At the conclusion of this continuing education activity, the participant will be able to:

• Recall the underlying pathophysiology of plaque psoriasis
• Review various treatment options for the management of patients with plaque psoriasis
• Identify patient considerations for pharmacotherapy selection